NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 6.9% After Insider Selling

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) were down 6.9% during mid-day trading on Wednesday following insider selling activity. The company traded as low as $24.25 and last traded at $23.8690. 167,541 shares were traded during trading, a decline of 84% from the average daily volume of 1,045,328 shares. The stock had previously closed at $25.63.

Specifically, Director John W. Smither sold 1,600 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the transaction, the director owned 8,760 shares of the company’s stock, valued at $221,803.20. This represents a 15.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday. Finally, Royal Bank Of Canada lowered their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.73.

Key Headlines Impacting NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $52 price target. Other analysts also maintain positive views, including BMO Capital Markets at $58, Jefferies at $45 and RBC at $50, supporting the longer-term outlook for NAMS. HC Wainwright rating report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests short selling is not a meaningful explanation for the recent decline, although the data may reflect an incomplete or anomalous report. NewAmsterdam Pharma market data
• Neutral Sentiment: Analyst reports discussing NAMS alongside Amgen, Dyne Therapeutics and Ionis Pharmaceuticals did not identify a new company-specific catalyst. Broader healthcare-sector commentary may influence sentiment but provides limited direct information about NewAmsterdam’s business. Healthcare analyst report
• Negative Sentiment: Director John W. Smither sold 1,600 shares for approximately $40,512, reducing his direct holdings by 15.44%. Although the sale may have been for personal reasons, it can reinforce investor caution during a period of market weakness. SEC insider transaction filing
• Negative Sentiment: NAMS reached a new one-year low following the insider-sale disclosure, signaling continued technical and investor-pressure concerns. The company also remains loss-making; its latest quarterly EPS missed expectations, and analysts forecast a full-year loss of about $1.82 per share. New one-year low report

NewAmsterdam Pharma Trading Down 4.1%

The business has a fifty day simple moving average of $28.84 and a two-hundred day simple moving average of $31.27. The company has a market cap of $2.61 billion, a PE ratio of -10.12 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently modified their holdings of NAMS. California State Teachers Retirement System increased its position in shares of NewAmsterdam Pharma by 4,105.5% during the 2nd quarter. California State Teachers Retirement System now owns 2,284,796 shares of the company’s stock worth $77,432,000 after purchasing an additional 2,230,467 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after buying an additional 1,145,128 shares during the period. Duquesne Family Office LLC boosted its holdings in NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the period. Castle Hook Partners LP purchased a new position in NewAmsterdam Pharma in the fourth quarter worth approximately $38,062,000. Finally, Adage Capital Partners GP L.L.C. increased its holdings in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.